STOCK TITAN

Lichen International closes $3.5M direct offering

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Lichen International Ltd (LICN) closed a registered direct offering of 17,500,000 units at $0.20 per unit on November 11, 2026, receiving $3.5 million in gross proceeds before placement-agent fees and estimated offering expenses. Each unit included one Series A ordinary share or one pre-funded warrant in lieu of it, plus one ordinary warrant. The company intends to use net proceeds for working capital and general corporate purposes.

By the reported date, purchasers had exercised pre-funded warrants for 13,900,000 Series A ordinary shares and ordinary warrants through the zero-exercise-price option for 14,986,000 shares, which the company issued. Ordinary warrants also allow an initial $0.20-per-share exercise or an alternative zero-price exercise for 4.72 Series A shares per warrant, subject to a 9.99% beneficial ownership limit. The company agreed to pay Univest Securities, LLC a 7.0% placement fee and a 1% expense allowance, plus expense reimbursement capped at $80,000. It also agreed to 30-calendar-day restrictions after closing on certain issuances, registration filings and variable-rate transactions, subject to exceptions; officers and directors agreed not to sell or dispose of shares for 90 days after closing.

Filing Explained

The report specifies that pre-funded warrants carried a $0.20-per-share exercise price; 13,900,000 shares issued on their exercise add to the share count, while the report does not quantify cash received from those exercises.

Offering size 17,500,000 units Registered direct offering closed November 11, 2026
Unit price $0.20 per unit Registered direct offering
Gross proceeds $3.5 million Before placement-agent fees and estimated offering expenses
Shares issued upon pre-funded warrant exercise 13,900,000 Series A ordinary shares Issued following purchaser exercises by the reported date
Shares issued upon ordinary warrant exercise 14,986,000 Series A ordinary shares Issued through the zero-exercise-price option by the reported date
Zero-exercise-price option 4.72 Series A ordinary shares per warrant Alternative ordinary warrant exercise method
Beneficial ownership limit 9.99% Limit applicable to warrant exercise
Placement agent fee 7.0% of aggregate gross proceeds Cash fee payable to Univest Securities, LLC
registered direct offering financial
"in a registered direct offering"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
Pre-Funded Warrant financial
"one pre-funded warrant to purchase one Series A Ordinary Share"
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
zero exercise price option financial
"through a zero exercise price option"
A zero exercise price option is a stock option that lets the holder convert the option into shares without paying any cash upfront because the strike price is set at zero. For investors, these awards act like immediate share grants: they increase the company’s outstanding shares (dilution), are treated as employee compensation for accounting and tax purposes, and signal how management is being paid, which can affect future earnings and shareholder value.
beneficial ownership limitation regulatory
"subject to a beneficial ownership limitation of 9.99%"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
variable rate transaction financial
"issuance of Series A Ordinary Shares or equivalent securities involving a variable rate transaction"
non-accountable expense allowance financial
"a non-accountable expense allowance equal to 1% of aggregate gross proceeds"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Lichen International Ltd (LICN) raise in its offering?

Lichen International Ltd received $3.5 million in gross proceeds from the offering, before placement-agent fees and estimated offering expenses. The offering consisted of 17,500,000 units priced at $0.20 each and closed on November 11, 2026.

How many LICN shares were issued after warrant exercises?

By the reported date, Lichen International Ltd had issued 13,900,000 Series A ordinary shares after purchasers exercised pre-funded warrants and 14,986,000 shares after purchasers exercised ordinary warrants through the zero-exercise-price option.

What are the LICN ordinary warrant exercise terms?

Each ordinary warrant initially permits the holder to purchase one Series A ordinary share for $0.20, or to use a zero-exercise-price option for 4.72 Series A ordinary shares. Exercise is subject to a 9.99% beneficial ownership limit.

What restrictions followed LICN's offering?

For 30 calendar days after closing, the company agreed to restrictions on certain securities issuances, registration filings and variable-rate transactions, subject to exceptions. The company's officers and directors agreed not to sell or dispose of their Series A ordinary shares for 90 days after closing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-41493

 

LICHEN INTERNATIONAL LIMITED

 

15th Floor, Xingang Square, Hubin North Road,

Siming District, Xiamen City,

Fujian Province, China, 361013

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

 

On November 10, 2026, Lichen International Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named thereto (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”),17,500,000 units (“Units”) at a purchase price of $0.20 per unit, each consisting of: (i) one series A ordinary share, par value US$0.008 per share (the “Series A Ordinary Share”), or one pre-funded warrant to purchase one Series A Ordinary Share (each, a “Pre-Funded Warrant” and the Series A Ordinary Shares underlying the Pre-Funded Warrants, the “Pre-Funded Warrant Shares”) in lieu thereof, and (ii) one ordinary warrant (an “Ordinary Warrant”). Each Ordinary Warrant is exercisable for one Series A Ordinary Share at an initial exercise price of US$0.20 per share or, at the holder’s election and subject to its terms, through a zero-price exercise for 4.72 Class A Ordinary Shares with up to 82,600,000 Series A Ordinary Shares (“Ordinary Warrant Shares”) issuable upon exercise of the Ordinary Warrants to purchase Series A Ordinary Shares at a zero exercise price.

 

The Offering closed on November 11, 2026. The Company received $3.5 million in gross proceeds from the Offering, before deducting placement agent fees and estimated offering expenses. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.

 

The Pre-Funded Warrants were sold to the Purchasers, whose purchase of the Series A Ordinary Shares in the Offering would otherwise have resulted in the Purchasers, together with its affiliates and certain related parties, beneficially owning more than 9.99% of the outstanding share capital of the Company following the consummation of the Offering, as elected by the Purchasers. Each Pre-Funded Warrant represents the right to purchase one Series A Ordinary Share at an exercise price of $0.20 per share. The Pre-Funded Warrants are exercisable immediately upon issuance, in whole or in part, and may be exercised at any time until exercised in full, subject to the beneficial ownership limitation described above. As of the date of this Report, the Purchasers have exercised the Pre-Funded Warrants to purchase an aggregate of 13,900,000 Series A Ordinary Shares, and the Company has issued 13,900,000 Series A Ordinary Shares in accordance with the terms of the Pre-Funded Warrants.

 

Each Ordinary Warrant entitles its holder to purchase one Series A Ordinary Share at an initial exercise price of US$0.20 per share, subject to customary adjustment and is exercisable beginning on the date of the issuance date and ending on the one year of the issuance date. Alternatively, The Ordinary Warrants include provisions for alternative cashless exercise, pursuant to which holders of Ordinary Warrants may effect a “zero exercise price option,” under which each Ordinary Warrant may be exercised for 4.72 Series A Ordinary Shares, without payment of additional exercise consideration, subject to the terms of the Ordinary Warrants. Exercise is subject to a beneficial ownership limitation of 9.99%, as elected by the Purchasers prior to issuance and subject to terms of the Ordinary Warrants. As of the date of this Report, the Purchasers have exercised the Ordinary Warrants, pursuant to the zero exercise price option, to purchase an aggregate of 14,986,000 Series A Ordinary Shares, and the Company has issued 14,986,000 Series A Ordinary Shares in accordance with the terms of the Ordinary Warrants.

 

The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties, and termination provisions.

 

In addition, the Company agreed that for a period of 30 calendar days after the closing date of the Offering, it will not: (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Series A Ordinary Shares or equivalent securities; or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement, a registration statement on Form S-8 in connection with any employee benefit plan and the Resale Registration Statement (as defined in the Purchase Agreement. The Company further agreed that, during the same period, it will not effect or enter into any agreement to effect any issuance of Series A Ordinary Shares or equivalent securities involving a variable rate transaction (as defined in the Purchase Agreement) for a period of 30 days after the closing date of the Offering, subject to certain exceptions set forth therein.

 

Concurrently with the execution of the Purchase Agreement, the officers and directors of the Company entered into lock-up agreements (the “Lock-Up Agreements”) pursuant to which they have agreed, among other things, not to sell or dispose of any Series A Ordinary Shares which are or will be beneficially owned by them for ninety (90) days following the closing of the Offering.

 

The Series A Ordinary Shares, the Pre-Funded Warrants, the Ordinary Warrants, the Pre-Funded Warrant Shares and the Ordinary Warrant Shares (together with the Series A Ordinary Shares, the Pre-Funded Warrants, the Ordinary Warrants and the Pre-Funded Warrant Shares, the “Securities”) were offered by the Company pursuant to a registration statement on Form F-3 (File No. 333-291878) (the “Registration Statement”), previously filed and declared effective by the Securities and Exchange Commission (the “Commission”) on December 10, 2025, the base prospectus filed as part of the Registration Statement, and the prospectus supplement dated November 10, 2026 (the “Prospectus Supplement”).

 

On November 10, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Univest Securities, LLC (“Univest” or the “Placement Agent”), pursuant to which the Company engaged Univest as the sole placement agent in connection with the Offering. The Placement Agent agreed to use its reasonable best efforts to arrange for the sale of the Shares, the Pre-Funded Warrants and the Ordinary Warrants. In addition, under the Placement Agency Agreement the Company agreed to pay the Placement Agent a placement agent fee in cash equal to 7.0% of the aggregate gross proceeds and a non-accountable expense allowance equal to 1% of aggregate gross proceeds raised from the sale. The Company also agreed to reimburse the Placement Agent for all reasonable out-of-pocket expenses, including legal and other reasonable expenses incurred by them in connection with the Offering in an amount not to exceed $80,000.

 

1

 

 

The Placement Agency Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Placement Agent, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions.

 

The foregoing summaries of the Placement Agency Agreement, the Purchase Agreement, the Lock-Up Agreements, the Pre-Funded Warrants and the Ordinary Warrants do not purport to be complete and are subject to, and qualified in their entirety by, such documents filed as Exhibits 10.1, 10.2, 10.3, 4.1 and 4.2, respectively, hereto and incorporated by reference herein.

 

Copy of the opinion of Appleby relating to the legality of the issuance and sale of the Securities is filed as Exhibits 5.1 hereto.

 

Copy of the press release related to the Offering entitled “Lichen International Limited Announces Pricing of $3.5 Million Registered Direct Offering” is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

 

This report is incorporated by reference into the registration statement on Form F-3 (File No. 333-291878) of the Company, filed with the Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

This report shall not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

Forward-Looking Statements

 

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include the risks and uncertainties described in the Company’s annual report on Form 20-F for the year ended December 31, 2025, filed with the Commission on April 28, 2026, and the Company’s other filings with the Commission, including interim reports. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

Exhibit Index

 

Exhibit No.   Description
4.1   Form of Pre-Funded Warrants
4.2   Form of Ordinary Warrants
5.1   Opinion of Appleby
10.1   Placement Agency Agreement, dated November 10, 2026, by and between the Company and Univest Securities, LLC
10.2   Form of Securities Purchase Agreement
10.3   Form of Lock-Up Agreements
23.1   Consent of Appleby (included in Exhibit 5.1)
99.1   Press Release

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Lichen International Limited
   
Date: November 12, 2026 By: /s/ Ya Li
  Name: Ya Li
  Title: Chief Executive Officer

 

3

Exhibit 99.1

 

Lichen International Limited Announces Pricing of $3.5 Million Registered Direct Offering

 

XIAMEN, China, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Lichen International Limited (NASDAQ: LICN) (the “Company”), a dedicated financial and taxation service provider in China, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of an aggregate of 17,500,000 units (each, a “Unit”), consisting of one Class A Ordinary Share (or one pre-funded warrant in lieu thereof) and one warrant to purchase 4.72 Class A Ordinary Shares (each, a “Warrant”), at an offering price of $0.20 per Unit in a registered direct offering (the “Offering”).

 

The gross proceeds to the Company from the registered direct offering are estimated to be approximately $3.5 Million before deducting the placement agent’s fees and other estimated offering expenses. Each of the Warrants will have an exercise price of $0.20 per Class A Ordinary Share, will be immediately exercisable upon issuance, and will expire on the one-year anniversary of the issuance date. The offering is expected to close on November 11, 2026, subject to the satisfaction of customary closing conditions.

 

Univest Securities, LLC is acting as the sole placement agent.

 

The registered direct offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-291878) previously filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) and became effective on December 10, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Univest Securities, LLC at info@univest.us, or by calling +1 (212) 343-8888.

 

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying base prospectus will be filed by the Company and, upon filing, can be obtained at the SEC’s website at www.sec.gov.

 

About Lichen International Limited

 

Lichen International Limited focuses on providing (i) financial and taxation solution services; (ii) education support services; (iii) software and maintenance services and (iv) Pre-IPO advisory services in the PRC under our “Lichen” brand. In recognition of the Company’s expertise and experience in the financial and taxation solution services industry for over 20 years, the Company has built up its reputation as a dedicated financial and taxation solution services provider of professional and high-quality services in China. For more information, please visit the Company’s website: https://ir.lichenzx.com/

 

Forward-Looking Statements

 

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.

 

For investor and media inquiries, please contact:

 

LICHEN INTERNATIONAL LIMITED

Tian Sun

Phone: +86-592-5586999

Email: ir@lichenzx.com

Filing Exhibits & Attachments

7 documents

Keep reading